Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation

Fig. 2

GRIM19 attenuates acute GVHD severity and inflammation. a Recipients (B/c mice) were intravenously injected with 5 × 106 donor (WT or GRIM19 Tg) bone marrow cells and 1 × 107 WT or GRIM19 Tg splenocytes after lethal irradiation. Histopathology results of the skin, liver, small intestine, and lung on day 14 after BMT (n = 12 per group) from one of two independent experiments are shown. Sections were stained with H&E (original magnification, ×200). b Histopathology score of the skin, liver, small intestine, and lung tissues. Results are expressed as mean ± SD from six mice. *p < 0.05, **p < 0.01. c Twelve days after BMT, serum levels of IgG in the three groups were measured by ELISA. Data are expressed as means ± SD from eight mice. *p < 0.05, **p < 0.01, ***p < 0.001. d Serum levels of IFN-γ, IL-17, and IL-10 in three groups were measured by ELISA. Data are expressed as means ± SD from eight mice. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page